Soros Fund Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Soros Fund Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-821,635	Closed	-$61.8M	–	300
2022 Q2	$61.8M	Buy	+821,635	New	+$36.5M	1.1%	28

Soros Fund Management's TPTX Position: Q3 2022 in Review

Soros Fund Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 821,635 shares — an estimated $61.8M sold.

Soros Fund Management first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $61.8M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Soros Fund Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Soros Fund Management sold 821,635 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $61.8M.
Soros Fund Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Soros Fund Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $61.8M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Soros Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.